Correvio Pharma Corp.

Period: 10/23/2018 to 12/05/2019
Lead Plaintiff Deadline: 02/10/2020

SUMMARY OF CASE:

A securities class action has been filed against Correvio Pharma Corp. (CORV) on behalf of a class consisting of all persons other than Defendants who purchased or otherwise acquired Correvio securities between October 23, 2018 through December 5, 2019.  This case has been filed in the USDC – S.D.N.Y.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies.  Specifically, Defendants made false and/or misleading statementsand/or failed to disclosethat: (i) the data supporting  the  Resubmitted  NDA  for  Brinavess  did  not minimizethe significant  health  and safety  issuesobserved  in  connection  with  the  drug’s  original  NDA;  (ii)  the  foregoing substantially diminished the likelihood that the FDA would approve the Resubmitted NDA; and (iii) as a result, the Company’s public statements were materially false and misleading at  all relevant times.